Analyst Ratings For AtriCure
AtriCure Analyst Ratings
Atricure's Competitive Landscape Clears: A Buy Rating Amid Delayed Threats and Growth Prospects
Analysts Offer Insights on Healthcare Companies: Atricure (ATRC), Immunovant (IMVT) and Monte Rosa Therapeutics (GLUE)
AtriCure Analyst Ratings
AtriCure Analyst Ratings
AtriCure's Strong Growth and Market Position Justify Buy Rating
Analysts Are Bullish on These Healthcare Stocks: Atricure (ATRC), Alkermes (ALKS)
AtriCure Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Atricure (ATRC) and Sight Sciences (SGHT)
AtriCure Analyst Ratings
UBS Adjusts AtriCure Price Target to $58 From $57, Maintains Buy Rating
Oppenheimer Sticks to Its Hold Rating for Atricure (ATRC)
Analysts Offer Insights on Healthcare Companies: Atricure (ATRC), Charles River Labs (CRL) and Shockwave Medical (SWAV)
Atricure's Strong Performance and Growth Potential Merit a Buy Rating
AtriCure Analyst Ratings
UBS Adjusts AtriCure Price Target to $57 From $56, Maintains Buy Rating
AtriCure's Growth Trajectory: A Strong Buy Rating With Revenue Surge and Strategic Expansions
Atricure's Strong Growth and Positive Outlook Justify Buy Rating
Analysts Offer Insights on Healthcare Companies: Atricure (ATRC), Ascendis Pharma (ASND) and G1 Therapeutics (GTHX)